Company
perfusetherapeutics
Developing novel therapies to reduce blindness.
Also known as Perfuse Therapeutics
- Status
- Acquiredas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- perfusetherapeutics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Perfuse Therapeutics is a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness. Our mission is to develop novel therapeutics to protect and improve the vision of patients with ocular diseases.
Funding snapshot
- Total raised
- $11MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $9M2020-07-15
Funding rounds
- Round, 2020
- $9M2020-07-15, SEC form D sold, 8 investors
- Round, 2019
- $2M2019-03-21, SEC form D sold, 6 investors
About the company
- Status notes
- Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
Products
- Web
- PER-001
- Other
- PER-001 Intravitreal Implant
Exit
- Acquisition
- 2026-05-06
Loading relationship preview